Brief: Biosynex Launches Range Of Tests Dedicated To Diagnosis Of COVID-19
March 26 (Reuters) - Biosynex SA ALBIO.PA :
* BIOSYNEX ANNOUNCES THE LAUNCH OF A RANGE OF TESTS
DEDICATED TO
THE DIAGNOSIS OF COVID-19
* SIGNATURE OF A DISTRIBUTION AGREEMENT WITH CREDO
DIAGNOSTICS
BIOMEDICAL LTD
Source text for Eikon: ID:nBw92PzdRa
Further company coverage: ALBIO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Biosynex SA
See all newsBrief: Biosynex FY Revenue Down To EUR 93.1 Million
Brief: Biosynex Announces Completion Of Merger-Absorption Of Theradiag
Brief: Biosynex Q3 Group Revenue Rises To EUR 24.4 Mln
Brief: Biosynex Announces Its Subsidiary Procisedx Acquires Two U.S. Patents
Brief: Biosynex's Procisedx Obtains First FDA Approvals